John Cox's appointment, with his vast biotech industry and r...
John Cox's appointment, with his vast biotech industry and rare disease commercialization experience, is viewed positively for Dyne Therapeutics. His leadership is anticipated to enhance the company's clinical programs and pipeline, and build more capabilities as Dyne continues to create stakeholder value.
Press Release: Dyne Therapeutics Announces CEO Transition
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment